Clinical Trial

Novel ERG for Detection of Hydroxychloroquine Retinopathy

Recruiting
View on ClinicalTrials.gov →
Record status
This record was last updated August 6, 2025 (before its estimated May 2026 completion). Its status may not reflect the trial's current state.
Summary
The purpose of the study is to investigate novel electroretinography (ERG) devices in the detection of hydroxychloroquine retinopathy. Two devices (the RETEval full-field and flicker ERG and UTAS multifocal ERG) will be evaluated in this study, comparing device outputs to standard of care screening tests, in groups of participants characterised by presence or absence of hydroxychloroquine-related retinopathy.
Protocol Amendment History 3 amendments
This ClinicalTrials.gov record has been amended 3 times since 2023-09-06; most recent amendment 2025-08-01.
Status change: Not Yet Recruiting → Recruiting 2024-07-22
Trial Details
NCT Number NCT06035887
Lead Sponsor King's College Hospital NHS Trust
Collaborators: LUPUS UK, King's College Hospital Charity
Conditions Hydroxychloroquine Retinopathy
Enrollment 140 participants
Start Date 2024-05-31
Primary Completion 2026-05 (estimated)
Study Completion 2026-05 (estimated)
Updated on ClinicalTrials.gov 2025-08-06